Health
Dozens of Clinical Trials Have Been Frozen in Response to Trump’s USAID Order
Asanda Zondi received a startling phone call last Thursday, with orders to make her way to a health clinic in Vulindlela, South Africa, where she was participating in a research study that was testing a new device to prevent pregnancy and H.IV. infection.
The trial was shutting down, a nurse told her. The device, a silicone ring inserted into her vagina, needed to be removed right away.
When Ms. Zondi, 22, arrived at the clinic, she learned why: The U.S. Agency for International Development, which funded the study, had withdrawn financial support and had issued a stop-work order to all organizations around the globe that receive its money. The abrupt move followed an executive order by President Trump freezing all foreign aid for at least 90 days. Since then, the Trump administration has taken steps to dismantle the agency entirely.
Ms. Zondi’s trial is one of dozens that have been abruptly frozen, leaving people around the world with experimental drugs and medical products in their bodies, cut off from the researchers who were monitoring them, and generating waves of suspicion and fear.
The State Department, which now oversees U.S.A.I.D., replied to a request for comment by directing a reporter to USAID.gov, which no longer contains any information except that all permanent employees have been placed on administrative leave. Secretary of State Marco Rubio has said that the agency is wasteful and advances a liberal agenda that is counter to President Trump’s foreign policy.
In interviews, scientists — who are forbidden by the terms of the stop-work order to speak with the news media — described agonizing choices: violate the stop-work orders and continue to care for trial volunteers, or leave them alone to face potential side effects and harm.
The United States is signatory to the Declaration of Helsinki that lays out ethical principles under which medical research must be conducted, requiring that researchers care for participants throughout a trial, and report the results of their findings to the communities where trials were conducted.
Ms. Zondi said she was baffled and frightened. She talked with other women who had volunteered for the study. “Some people are afraid because we don’t know exactly what was the reason,” she said. “We don’t really know the real reason of pausing the study.”
The stop-work order was so immediate and sweeping that the research staff would be violating it if they helped the women remove the rings. But Dr. Leila Mansoor, a scientist with the Centre for the AIDS Programme of Research in South Africa (known as CAPRISA) and an investigator on the trial, decided she and her team would do so anyway.
“My first thought when I saw this order was, There are rings in people’s bodies and you cannot leave them,” Dr. Mansoor said. “For me ethics and participants come first. There is a line.”
In the communities where her organization works, people have volunteered for more than 25 years to test H.I.V. treatments, prevention products and vaccines, contributing to many of the key breakthroughs in the field and benefiting people worldwide.
That work relied on a carefully constructed web of trust that has now been destroyed, Dr. Mansoor said. Building that trust took years in South Africa, where the apartheid regime conducted medical experiments on Black people during the years of white rule. Those fears are echoed in a long history of experimentation by researchers and drug companies in developing countries and in marginalized populations in the United States.
The Times identified more than 30 frozen studies that had volunteers already in the care of researchers, including trials of:
-
malaria treatment in children under age 5 in Mozambique
-
treatment for cholera in Bangladesh
-
a screen-and-treat method for cervical cancer in Malawi
-
tuberculosis treatment for children and teenagers in Peru and South Africa
-
nutritional support for children in Ethiopia
-
early-childhood-development interventions in Cambodia
-
ways to support pregnant and breastfeeding women to reduce malnutrition in Jordan
-
an mRNA vaccine technology for H.I.V. in South Africa
It is difficult to know the total number of trials shut down, or how many people are affected, because the swift demolition of U.S.A.I.D. in recent days has erased the public record. In addition to the disabled website, the agency no longer has a communications department. And the stop-work order prohibits any implementing agency from speaking publicly about what has happened.
In England, about 100 people have been inoculated with an experimental malaria vaccine in two clinical trials. Now, they no longer have access to the clinical trial staff if that vaccine were to cause an adverse reaction in their bodies. The trial is an effort to find a next-generation vaccine better than the one now used in Africa; that shot protects children against about a third of malaria cases, but researchers hoped to find a vaccine that offered much more protection. Malaria remains a top global killer of children; 600,000 people died of the disease in 2023, the latest figure available.
Had the trial not been frozen, the participants would be coming to a clinic routinely to be monitored for adverse physical effects, and to have blood and cell samples taken to see whether the vaccine was working. The participants are meant to be followed for two years to assess the vaccine’s safety.
A scientist who worked on the trial said she hoped that partners at the University of Oxford, where it was being conducted, were shuffling staff to respond if any participant fell ill. But she was fired last week and no longer has access to any information about the trial. She spoke on condition of anonymity because she feared jeopardizing her ability to work on malaria research the U.S. might conduct in the future.
“It’s unethical to test anything in humans without taking it to the full completion of studies,” she said. “You put them at risk for no good reason.”
Had the stop-work order come later this year, the newly-vaccinated volunteers might have been in an even more precarious position. They were scheduled to be deliberately infected with malaria to see if the experimental vaccine protected them from the disease.
Dr. Sharon Hillier, a professor of reproductive infectious diseases at the University of Pittsburgh, was until this week director of a five-year, $125 million trial funded by U.S.A.I.D. to test the safety and efficacy of six new H.I.V. prevention products. They included bimonthly injections, fast-dissolving vaginal inserts and vaginal rings.
With the study suspended, she and her colleagues cannot process biological samples, analyze the data they have already collected, or communicate findings to either participants or the partnering government agencies in countries where the trials were conducted. These are requirements under the Helsinki agreement.
“We have betrayed the trust of ministries of health and the regulatory agencies in the countries where we were working and of the women who agreed to be in our studies, who were told that they would be taken care of,” Dr. Hillier said. “I’ve never seen anything like it in my 40 years of doing international research. It’s unethical, it’s dangerous and it’s reckless.”
Even trials that were not funded in whole or part by U.S.A.I.D. have been thrown into turmoil because they were using medical or development infrastructure that was supported by the agency and is no longer operational. Millions of dollars of U.S. taxpayer funds already spent to start those trials will not be recouped.
The shutdowns have business consequences as well. Many of those trials were partnerships with U.S. drug companies, testing products they hoped to sell overseas.
“This has made it impossible for pharmaceutical companies to do research in these countries,” Dr. Hillier said.
Another H.I.V. trial, called CATALYST, has thousands of volunteers in five countries testing an injectable drug called long-acting cabotegravir. Participants were receiving bimonthly injections to maintain a sufficient level of the drug in their bodies to prevent H.I.V. infection. Without regular injections, or a carefully-managed end to use of the drug, the participants will not have enough cabotegravir to stop a new infection, but there will be enough in their systems that, if they were to contract the virus, it could easily mutate to become drug-resistant, said Dr. Kenneth Ngure, president-elect of the International AIDS Society.
This is a significant threat to the trial volunteers and also to the millions of people living with H.I.V. because cabotegravir is closely related to a drug that is already used worldwide in standard treatment of the virus. Development of resistance could be catastrophic, Dr. Ngure said: “It’s wrong on so many levels — you can’t just stop.”
A clinical trial run by the development organization FHI 360, which implemented many U.S.A.I.D.-funded health programs and studies, was testing a biodegradable hormonal implant to prevent pregnancy. Women in the Dominican Republic had the devices in their bodies when U.S.A.I.D. funding was cut off. A spokeswoman for the organization, which furloughed more than a third of its staff this week, said that it had pulled together other resources to ensure that participants continue to receive care.
Another trial, in Uganda, was testing a new regimen of tuberculosis treatment for children. The stop-work order cuts those children off from potentially lifesaving medication.
“You can’t walk away from them, you just can’t,” a researcher in that trial said.
NEWYou can now listen to Fox News articles!
South Carolina is facing a major measles outbreak, resulting in the quarantine of hundreds of residents.
The South Carolina Department of Health (DPH) reported in a media briefing on Wednesday that the current number of measles cases has reached 111 as part of the current Spartanburg County outbreak.
DPH first reported a measles outbreak in the Upstate region on Oct. 2.
CLICK HERE FOR MORE HEALTH STORIES
The health department confirmed that 254 people are currently in quarantine and 16 are in isolation to prevent further spread.
The health department confirmed that 254 people are currently in quarantine in the upstate region. (Getty Images)
“This significant jump in cases is unfortunate,” a DPH spokesperson commented on the outbreak.
Public exposure was identified at Inman Intermediate School, with 43 of their students in quarantine.
“This significant jump in cases is unfortunate.”
Eight other intermediate and middle schools in the area are also reportedly undergoing quarantine. The DPH said multiple students have had to quarantine twice due to repeat exposure.
“Vaccination continues to be the best way to prevent the disruption that measles is causing to people’s education, to employment and other factors in people’s lives and our communities,” the spokesperson said.
“This significant jump in cases is unfortunate,” a DPH spokesperson commented on the current outbreak. (iStock)
Out of the 111 confirmed cases, 105 were unvaccinated. Receiving a vaccination within 72 hours has been shown to prevent measles infection, the DPH spokesperson noted.
Some cases are related to travel exposure, while others are from an unknown source, suggesting that measles is circulating in the community, the DPH noted.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
Connecticut has also reported its first measles case in four years, according to the Connecticut Department of Public Health.
The department confirmed on Thursday that an unvaccinated child in Fairfield County, under the age of 10, was diagnosed with measles after recently traveling internationally.
“Vaccination continues to be the best way to prevent the disruption that measles is causing,” a DPH spokesperson said. (iStock)
The child began to show symptoms several days later, including a runny nose, cough, congestion, fever and a rash starting at the head and spreading to the rest of the body.
The Connecticut DPH noted that measles is “highly contagious” and can spread quickly through the air via coughing or sneezing. The CDC has estimated that nine out of 10 unvaccinated individuals who encounter an infected person will develop the measles virus.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
According to the International Vaccine Access Center, more than 1,800 cases of measles have been reported in 2025, which is the most since the U.S. declared the virus eliminated in 2000. It is also the most cases recorded in three decades.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
“The single best way to protect your children and yourself from measles is to be vaccinated,” DPH Commissioner Manisha Juthani, M.D., wrote in a statement. “One dose of measles vaccine is about 93% effective, while two doses are about 97% effective.”
NEWYou can now listen to Fox News articles!
A sperm donor whose samples helped conceive nearly 200 children across Europe unknowingly carried a cancer-causing genetic mutation — a hidden risk now tied to multiple childhood illnesses and early deaths.
An investigation led by the BBC and many other public service broadcasters revealed that the donations were made to Denmark’s European Sperm Bank (ESB). Those donations were then used by 67 fertility clinics in 14 countries over a 17-year span.
The donor, who was not identified, was paid to donate as a student beginning in 2005, according to the report.
ROBOTS POWER BREAKTHROUGH IN PREGNANCY RESEARCH, BOOSTING IVF SUCCESS RATES
Although the donor passed the initial health screenings, he had hidden genetic mutations that damaged the TP53 gene, which helps to prevent cancer by repairing DNA damage or trigger the death of cancer cells.
When TP53 is mutated, those protective functions are lost, which can lead to uncontrolled cell division, accumulation of mutations and tumor growth, research has shown.
A sperm donor whose samples helped conceive nearly 200 children across Europe (not pictured) unknowingly carried a cancer-causing genetic mutation — a hidden risk now tied to multiple childhood illnesses and early deaths. (Getty Images)
Up to 20% of the man’s sperm would contain that mutated gene, and any children conceived from that affected sperm would have the mutation in every cell of their body, the BBC report stated.
As a result, these children would have a 90% risk of developing some type of cancer in their lifetime, including breast cancer, bone cancers, brain tumors and leukemia. This heightened risk is known as Li Fraumeni syndrome.
THREE-PERSON IVF TECHNIQUE SHOWN TO PREVENT INHERITED GENETIC DISEASES
Doctors raised these concerns at the annual congress of the European Society of Human Genetics (ESHG), which was held in Milan in May 2025.
At that conference, Edwige Kasper — a specialist in cancer genetics at Rouen University Hospital in France — presented the case of the sperm donor whose genetic material carried the harmful variant.
“This is the abnormal dissemination of genetic disease. Not every man has 75 children across Europe.”
It was reported that 23 children had been confirmed to have the variant at that time, 10 of which had already been diagnosed with cancer.
The actual number is likely much higher, the report surmised, as at least 197 children were born from the donated sperm — but not all data has been collected.
Kasper called for a limit on the number of births or families for a single donor in Europe.
“We can’t do whole-genome sequencing for all sperm donors — I’m not arguing for that,” she said. “But this is the abnormal dissemination of genetic disease. Not every man has 75 children across Europe.”
SKIN DNA BREAKTHROUGH COULD LET 60-YEAR-OLD WOMEN HAVE GENETICALLY RELATED KIDS
She also recommended that children born from this donor’s sperm undergo genetic counseling.
“We have some children that have already developed two different cancers, and some of them have already died at a very early age,” Kasper recently told the investigators.
Up to 20% of the man’s sperm would contain that mutated gene, and any children conceived from that affected sperm would have the mutation in every cell of their body, the BBC report stated. (iStock)
There is no worldwide law that limits how many times a donor’s sperm can be used or how many children may be born from a single donor, according to the European Society of Human Reproduction and Embryology (ESHRE).
However, individual countries may have their own rules or guidelines surrounding sperm donor usage. The ESHRE recently proposed a cap of 50 families per donor as an international limit.
HOW AI IS MAKING IVF MORE PREDICTABLE
Dr. Marc Siegel, Fox News senior medical analyst, commented on these developments to Fox News Digital.
“This awful story emphasizes the growing need for up-to-date genetic screening for all donors,” he said. “It also provides context for the idea that knowing the donor provides an advantage.”
“This awful story emphasizes the growing need for up-to-date genetic screening for all donors,” Dr. Marc Siegel said. (iStock)
“Genetic screening, including for oncogenes (genes that have the potential to cause cancer) is improving dramatically, and all use of sperm donations must include it,” Siegel went on.
He also called for AI to be used to improve and speed up the process.
“When a propensity for disease is suspected, the sperm must be discarded,” the doctor added.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
In a statement sent to Fox News Digital, the European Sperm Bank expressed “deepest sympathy” for the families involved.
“We are deeply affected by the case and the impact that the rare TP53 mutation has on a number of families, children and the donor. They have our deepest sympathy,” the ESP said.
The American Society of Reproductive Medicine provided its guidance on embryo and gamete donation, which stated in part that all prospective donors should undergo “appropriate genetic evaluation.” (iStock)
“ESB tests and performs an individual medical assessment of all donors in full compliance with recognized and scientific practice and legislation.”
In the case of this particular sperm donor with the TP53 mutation, the ESB noted that it occurs only in a small part of the donor’s sperm cells and not in the rest of the body.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
“In such cases, the donor himself and his family members are not ill, and a mutation of this type is not detected preventively by genetic screening,” the agency said.
When the ESB later confirmed the mutation in 2023, the donor was “immediately blocked” and authorities and clinics were notified.
“Donors should be healthy and have no history to suggest hereditary disease.”
“The clinics are responsible for informing the patients, partly because we as a sperm bank do not necessarily know the patients, and because the patients’ own treating physicians are best equipped to advise them in the specific situation,” the agency stated.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
When contacted by Fox News Digital, the American Society of Reproductive Medicine (ASRM) provided its guidance on embryo and gamete donation, which stated in part that all prospective donors should undergo “appropriate genetic evaluation.”
“Donors should be healthy and have no history to suggest hereditary disease,” the ASRM continued.
CLICK HERE FOR MORE HEALTH STORIES
Parents with concerns are encouraged to contact both their treating clinic and the relevant fertility authority in that country.
GLP-1 weight loss pill in development
Fox News senior medical analyst Dr. Marc Siegel discusses advancements in weight loss drugs, safety concerns surrounding nicotine patches and his interview with FDA Commissioner Dr. Marty Makary on vaccine protocol.
NEWYou can now listen to Fox News articles!
Scientists in Sweden have created a new pill designed to help the body burn fat and control blood sugar in a different way than popular GLP-1 drugs, like Ozempic.
While injectable GLP-1s work by suppressing appetite, this new treatment boosts metabolism in the muscles.
A study led by researchers at Karolinska Institutet and Stockholm University included both an early animal study and a human clinical trial with 48 healthy adults and 25 people with type 2 diabetes, according to a press release.
NEW WEIGHT-LOSS SHOT SHOWS MAJOR FAT REDUCTION, BUT EXPERTS URGE CAUTION
The new oral medication was found to successfully control blood glucose, boost fat burning and retain muscle mass in animals, while getting high marks for tolerability and safety in humans.
It was also found to have fewer side effects than GLP-1s like semaglutides and tirzepatides, which are known to cause appetite loss, gastrointestinal distress and muscle wasting, the researchers noted.
While injectable GLP-1s work by suppressing appetite, this new treatment boosts metabolism in the muscles. (iStock)
The experimental medication uses a new form of beta-2 agonist that benefits muscle function while also avoiding overstimulation of the heart, which has been identified as a potential safety concern of older versions.
The findings were published this week in the journal Cell.
WEIGHT-LOSS DRUGS NOW LINKED TO CANCER PROTECTION IN WOMEN, MAJOR NEW STUDY REVEALS
Because the new oral drug acts via a different mechanism than appetite-suppressing medications, it could be used alone or in combination with GLP-1s, the researchers noted.
“Our results point to a future where we can improve metabolic health without losing muscle mass,” said Tore Bengtsson, professor at the Department of Molecular Bioscience at Wenner-Gren Institute, Stockholm University, in the release. “Muscles are important in both type 2 diabetes and obesity, and muscle mass is also directly correlated with life expectancy.”
“Muscles are important in both type 2 diabetes and obesity, and muscle mass is also directly correlated with life expectancy.” (iStock)
This medication has the potential to be of “great importance” for patients with type 2 diabetes and obesity, according to Shane C. Wright, assistant professor at the Department of Physiology and Pharmacology at Karolinska Institutet.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
“Our substance appears to promote healthy weight loss and, in addition, patients do not have to take injections,” he added.
Dr. Trey Wickham, interim chief of the Division of Endocrinology, Diabetes & Metabolism at VCU Health in Richmond, Virginia, was not involved in the study but shared his reaction to the publication in the journal Cell.
“Our results point to a future where we can improve metabolic health without losing muscle mass.”
“This compound’s mechanism of action could address some specific metabolic concerns with previous weight reduction therapies, such as the loss of both muscle and fat tissue,” Wickham told Fox News Digital.
“Although the reported preliminary results are interesting, rigorous testing involving larger longitudinal trials are necessary to ensure human long-term safety and understand the potential role of this compound in the comprehensive, evidence-based treatment of obesity and diabetes.”
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
The study had some limitations, the researchers noted, chiefly that the preclinical studies in mice fail to capture the “complex nature of these diseases” in humans.
Structural studies are needed to understand exactly how the drug works.
“This compound’s mechanism of action could address some specific metabolic concerns with previous weight reduction therapies, such as the loss of both muscle and fat tissue,” a doctor said. (iStock)
“Our phase 1 data show that compound 15 is well-tolerated; however, conclusive clinical efficacy data (on how the drug controls glucose metabolism) are currently still lacking.”
CLICK HERE FOR MORE HEALTH STORIES
Looking ahead, the company that developed the drug, Atrogi AB, plans to conduct a larger phase 2 clinical trial with a larger, more diverse population, including people with obesity.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
The study was supported in part by the Swedish Research Council, the Swedish Society for Medical Research and the Novo Nordisk Foundation.
Uppsala University, University of Copenhagen, Monash University and University of Queensland all collaborated with the lead researchers.
Oilers turn in smart, defensive game and Hyman hat trick for 4-1 win over Detroit: Cult of Hockey Player Grades
San Francisco firefighters to retire uniforms linked to cancer
‘Finish the Fight’: Cancer survivor’s artwork inspires Dallas Stars fans after beating rare blood disease
The old Bucks shine in upset over Boston
Game Thread: Denver Nuggets vs Sacramento Kings. December 11th, 2025. – Denver Stiffs
Florida High School Football Rankings: Top 25 teams – Oct. 21
Cleary's 21 help Le Moyne down Central Connecticut State 69-64 in OT
How old is Bo Nix? What to know about Oregon quarterback ahead of 2024 NFL Draft
99th annual Pony Swim held in Virginia
Video: ‘It Didn’t Have to Happen This Way:’ U.Va. Faculty Call for Review of Police Response to Protests
Video: Hiker Rescued From Quicksand in Arches National Park
The Speaker’s Lobby: What Congress’ December script means for healthcare next year
Coalition of the Willing calls for transatlantic unity for Ukraine
In a setback for Trump, Indiana lawmakers defeat redistricting plan
House Dem to force Trump impeachment vote on 2 articles
-
Alaska6 days agoHowling Mat-Su winds leave thousands without power
-
Politics1 week agoTrump rips Somali community as federal agents reportedly eye Minnesota enforcement sweep
-
Ohio1 week agoWho do the Ohio State Buckeyes hire as the next offensive coordinator?
-
Texas6 days agoTexas Tech football vs BYU live updates, start time, TV channel for Big 12 title
-
News1 week agoTrump threatens strikes on any country he claims makes drugs for US
-
World1 week agoHonduras election council member accuses colleague of ‘intimidation’
-
Washington3 days agoLIVE UPDATES: Mudslide, road closures across Western Washington
-
Iowa5 days agoMatt Campbell reportedly bringing longtime Iowa State staffer to Penn State as 1st hire